← back to search

Saundra S. Buys

University of Utah · US
Area of research
Genetics · Oncology
Research interest
Research interests include BRCA gene mutations in cancer, Cancer Risks and Factors, Nutrition, Genetics, and Disease, and Nutritional Studies and Diet.
h-index
86
citations
37,224
works
482
NIH funding
primary concept
Medicine
email

Recent publications

Uptake of Cancer Genetic Services for Chatbot vs Standard-of-Care Delivery Models
JAMA Network Open 2024cited by 39position: lastdoi
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i>
Journal of Clinical Oncology 2024cited by 21position: middledoi
Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk
medRxiv 2024cited by 3position: middledoi
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
Journal of the National Comprehensive Cancer Network 2023cited by 275position: middledoi
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer
JCO Oncology Practice 2023cited by 73position: lastdoi
Prospective Pilot Study of <sup>18</sup>F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas
American Journal of Roentgenology 2023cited by 29position: middledoi
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival
Journal of Clinical Oncology 2023cited by 26position: middledoi
Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: The IMAGINE Study
Radiology 2023cited by 20position: middledoi
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry
Genome Medicine 2023cited by 15position: middledoi
Association of the <scp> <i>CHEK2</i> </scp> c. <scp>1100delC</scp> variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival
Cancer Medicine 2023cited by 10position: middledoi
A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants: Application to BRCA1 and BRCA2
Human Mutation 2023cited by 6position: middledoi
Abstract 4176: Timing of pregnancy-related factors and breast cancer risk for women across a range of absolute risk
Cancer Research 2023cited by 0position: middledoi
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology
Nature Cancer 2022cited by 387position: middledoi
Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study
British Journal of Sports Medicine 2022cited by 96position: middledoi
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European Journal of Human Genetics 2022cited by 68position: middledoi
Association of Disparities in Family History and Family Cancer History in the Electronic Health Record With Sex, Race, Hispanic or Latino Ethnicity, and Language Preference in 2 Large US Health Care Systems
JAMA Network Open 2022cited by 44position: middledoi
Common variants in breast cancer risk loci predispose to distinct tumor subtypes
Breast Cancer Research 2022cited by 31position: middledoi
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications Biology 2022cited by 14position: middledoi
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European Journal of Human Genetics 2022cited by 4position: middledoi
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2021cited by 1,112position: middledoi
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
The Lancet Oncology 2021cited by 92position: middledoi
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker
BMC Cancer 2021cited by 49position: middledoi
Breast and Prostate Cancer Risks for Male<i>BRCA1</i>and<i>BRCA2</i>Pathogenic Variant Carriers Using Polygenic Risk Scores
JNCI Journal of the National Cancer Institute 2021cited by 41position: middledoi
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
Nature Communications 2021cited by 39position: middledoi
Patient Interactions With an Automated Conversational Agent Delivering Pretest Genetics Education: Descriptive Study
Journal of Medical Internet Research 2021cited by 38position: middledoi
Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial
BMC Health Services Research 2021cited by 38position: middledoi
Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants
JAMA Oncology 2021cited by 33position: middledoi
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
Breast Cancer Research 2021cited by 22position: middledoi
Common variants in breast cancer risk loci predispose to distinct tumor subtypes.
Apollo (University of Cambridge) 2021cited by 6position: middledoi
Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
Nature Communications 2021cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Esther M. John · Palo Alto University17 papers (2013–2023)Mary B. Daly · Fox Chase Cancer Center16 papers (2013–2021)Irene L. Andrulis · University of Toronto16 papers (2013–2021)Mary Beth Terry · Columbia University Irving Medical Center16 papers (2015–2023)John L. Hopper · National Institute on Deafness and Other Communication Disorders13 papers (2013–2023)Wendy K. Chung · Oregon Health & Science University12 papers (2013–2019)Julia A. Knight · Lunenfeld-Tanenbaum Research Institute11 papers (2015–2019)Melissa C. Southey · Monash Health8 papers (2015–2019)David E. Goldgar · University of Utah7 papers (2013–2019)Yuyan Liao · Columbia University7 papers (2015–2023)Roger L. Milne · Monash Institute of Medical Research7 papers (2013–2019)Amanda Gammon · University of Utah7 papers (2014–2024)Wendy Kohlmann · University of Utah7 papers (2017–2024)Gord Glendon · Lunenfeld-Tanenbaum Research Institute7 papers (2018–2019)Robert J. MacInnis · Cancer Council Victoria7 papers (2018–2021) · 6 papers (2018–2019)Gillian S. Dite · Columbia University6 papers (2018–2019)Graham G. Giles · Monash Institute of Medical Research6 papers (2018–2019)Kelly‐Anne Phillips · University of Alabama6 papers (2015–2019)Philip C. Prorok · National Cancer Institute5 papers (2012–2016)